Cameron A. Carter

Array ( [id] => 20458257 [patent_doc_number] => 20260007677 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-08 [patent_title] => STIMULANT COMPOSITION AND PROCESS FOR MAKING SAME [patent_app_type] => utility [patent_app_number] => 19/323694 [patent_app_country] => US [patent_app_date] => 2025-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1072 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19323694 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20393152 [patent_doc_number] => 20250368627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-04 [patent_title] => PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS [patent_app_type] => utility [patent_app_number] => 19/304725 [patent_app_country] => US [patent_app_date] => 2025-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25903 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 230 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19304725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20414134 [patent_doc_number] => 12497404 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Morphic forms of trilaciclib and methods of manufacture thereof [patent_app_type] => utility [patent_app_number] => 19/182977 [patent_app_country] => US [patent_app_date] => 2025-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 99 [patent_no_of_words] => 50376 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19182977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20136168 [patent_doc_number] => 20250243212 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-31 [patent_title] => MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF [patent_app_type] => utility [patent_app_number] => 19/182966 [patent_app_country] => US [patent_app_date] => 2025-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50286 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19182966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20136170 [patent_doc_number] => 20250243214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-31 [patent_title] => MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF [patent_app_type] => utility [patent_app_number] => 19/182985 [patent_app_country] => US [patent_app_date] => 2025-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50359 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19182985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19862244 [patent_doc_number] => 20250101030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF [patent_app_type] => utility [patent_app_number] => 18/973646 [patent_app_country] => US [patent_app_date] => 2024-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54594 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18973646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19585042 [patent_doc_number] => 20240382599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/623722 [patent_app_country] => US [patent_app_date] => 2024-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 94670 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18623722 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19279800 [patent_doc_number] => 20240216272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => PHARMACEUTICAL PREPARATION [patent_app_type] => utility [patent_app_number] => 18/608109 [patent_app_country] => US [patent_app_date] => 2024-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18608109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380874 [patent_doc_number] => 20240270744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => NEW PYRIDO DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM [patent_app_type] => utility [patent_app_number] => 18/441558 [patent_app_country] => US [patent_app_date] => 2024-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15733 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18441558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19387851 [patent_doc_number] => 20240277721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => COMBINATION THERAPY FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/431262 [patent_app_country] => US [patent_app_date] => 2024-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39096 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18431262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097645 [patent_doc_number] => 20240116873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => QUINOLINE MERCAPTOACETATE SULFONAMIDE DERIVATIVE, INTERMEDIATE, PHARMACEUTICAL DERIVATIVE OR FORMULATION, AND PREPARATION METHOD AND USE THEREFOR [patent_app_type] => utility [patent_app_number] => 18/514302 [patent_app_country] => US [patent_app_date] => 2023-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7563 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18514302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19186168 [patent_doc_number] => 20240165081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF INSOMNIA [patent_app_type] => utility [patent_app_number] => 18/514697 [patent_app_country] => US [patent_app_date] => 2023-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18514697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19049208 [patent_doc_number] => 20240091177 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/511036 [patent_app_country] => US [patent_app_date] => 2023-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23350 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18511036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20458201 [patent_doc_number] => 20260007621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-08 [patent_title] => Pharmaceutical Combinations for Treatment [patent_app_type] => utility [patent_app_number] => 19/124744 [patent_app_country] => US [patent_app_date] => 2023-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19124744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19417286 [patent_doc_number] => 20240293409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE [patent_app_type] => utility [patent_app_number] => 18/372495 [patent_app_country] => US [patent_app_date] => 2023-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25305 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18372495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19417285 [patent_doc_number] => 20240293408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE [patent_app_type] => utility [patent_app_number] => 18/372398 [patent_app_country] => US [patent_app_date] => 2023-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31773 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 300 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18372398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097663 [patent_doc_number] => 20240116891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => MARALIXIBAT SOLID FORMS, INTERMEDIATES AND PROCESSES OF MAKING SAME [patent_app_type] => utility [patent_app_number] => 18/368041 [patent_app_country] => US [patent_app_date] => 2023-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18368041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18769477 [patent_doc_number] => 20230364243 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS [patent_app_type] => utility [patent_app_number] => 18/362634 [patent_app_country] => US [patent_app_date] => 2023-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27914 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18362634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18709103 [patent_doc_number] => 20230331696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => SALT FORM OF ISOQUINOLINONE TYPE COMPOUND AS ROCK INHIBITOR AND PREPARATION METHOD THEREFOR [patent_app_type] => utility [patent_app_number] => 18/338355 [patent_app_country] => US [patent_app_date] => 2023-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18338355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430885 [patent_doc_number] => 20240299383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => IMMUNOMODULATOR COMPOSITION COMPRISING AZVUDINE [patent_app_type] => utility [patent_app_number] => 18/205628 [patent_app_country] => US [patent_app_date] => 2023-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4732 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18205628 [rel_patent_id] =>[rel_patent_doc_number] =>)